YAVNE, Israel, May 22, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), the global leader in next-generation enzymatic therapeutics for tissue repair, today announced that the Company will release its financial results for the first quarter ended March 31, 2024 on Wednesday, May 29, 2024. Following the release, management will host a conference call and live webcast at 8:30 am Eastern Time to discuss the financial results, provide corporate updates, and answer questions. MediWound Contacts: | Hani Lu ...

MediWound (MDWD) shares soared 14.3% in the last trading session to close at $18.28. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 1.7% gain over the past four weeks.Last month, the company announced robust financial results for the full year and fourth quarter ended 2023. This might have been driving the share price rally.This developer of treatments for burns and hard-to-heal wounds is expected to post quarterly loss of $0.40 ...

Company Highlights 14 successful clinical trials 120+ peer-reviewed publications Key approvals: FDA/EMA/JPN Significant commercial growth potential | --- | --- ...

MediWound Ltd. (NASDAQ:MDWD) Q4 2023 Earnings Conference Call March 21, 2024 8:30 AM ET Company Participants Gaia Shamis - LifeSci Advisors Ofer Gonen - Chief Executive Officer Barry Wolfenson - Executive Vice President of Strategy & Corporate Development Hani Luxenburg - Chief Financial Officer Conference Call Participants Joshua Jennings - TD Cowen Francois Brisebois - Oppenheimer Swayampakula Ramakanth - HC Wainwright Michael Okunewitch - Maxim Group Operator Good day, and welcome to MediWound’s Fourth Q ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________________ to ____________________ OR ☐ SHELL COMPANY REPORT P ...

Exhibit 99.1 MediWound Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update $19 million revenue in 2023; $24 million projected revenue in 2024 NexoBrid® commercially launched in U.S., Japan, India Potential blockbuster EscharEx® to begin Phase III in the second half of 2024 $42 million cash runway through profitability Conference call today, March 21 at 8:30am Eastern Time YAVNE, Israel, March 21, 2024 -- MediWound Ltd. (Nasdaq: MDWD), the global leader in next-generation ...

MediWound Ltd. (NASDAQ:MDWD) Q3 2023 Earnings Call Transcript November 21, 2023 8:30 AM ET Company Participants Daniel Ferry - LifeSci Advisors Ofer Gonen - Chief Executive Officer Barry Wolfenson - Executive Vice President of Strategy & Corporate Development Hani Luxenburg - Chief Financial Officer Conference Call Participants Francois Brisebois - Oppenheimer Michael Okunewitch - Maxim Group Operator Good day, and welcome to MediWound Third Quarter 2023 Earnings Call. [Operator Instructions]. Please note, ...

Exhibit 99.1 MediWound Reports Third Quarter 2023 Financial Results and Provides Company Update NexoBrid® commercially launched in U.S. and Japan; Company prioritizes operational resources to meet increased global demand EscharEx® Phase III study preparations progressing; Protocol submission to FDA expected in first quarter 2024 Cash of $46 million; Operating cash runway through profitability Conference call on Tuesday, November 21 at 8:30 a.m. Eastern Time YAVNE, Israel, November 21, 2023 -- MediWound Ltd. ...

MediWound Ltd. (NASDAQ:MDWD) Q2 2023 Earnings Call Transcript August 16, 2023 8:30 AM ET Company Participants Monique Kosse - LifeSci Advisors, IR Ofer Gonen - Chief Executive Officer Barry Wolfenson - Executive Vice President of Strategy & Corporate Development Hani Luxenburg - Chief Financial Officer Conference Call Participants Josh Jennings - TD Cowen Francois Brisebois - Oppenheimer Swayampakula Ramakanth - H.C. Wainwright Michael Okunewitch - Maxim Group Harold Weber - Aegis Capital Operator Good day, ...

Exhibit 99.2 MEDIWOUND LTD. AND ITS SUBSIDIARIES CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS AS OF JUNE 30, 2023 IN U.S. DOLLARS IN THOUSANDS UNAUDITED INDEX | Page | | | --- | --- | | Unaudited Condensed Interim Consolidated Statements of Financial Position | F-2 | | Unaudited Condensed Interim Consolidated Statements of Profit or Loss and Other Comprehensive Income | F-3 | | or Loss | | | Unaudited Condensed Interim Consolidated Statements of Changes in Shareholders' Equity (Deficit) | F-4 – F-5 | ...